Non-invasive assessment in MASLD: from biomarker discovery to clinical pathway integration

Metabolic dysfunction-associated steatotic liver disease (MASLD) is one of the leading causes of chronic liver disease worldwide. Although liver biopsy remains the histological reference standard for assessing steatohepatitis, fibrosis stage, and therapeutic response, its invasiveness, sampling variability, and limited suitability for repeated monitoring have driven the development of non-invasive approaches. Clinical scores based on routine variables, omics-derived biomarkers, quantitative imaging techniques, and multimodal integrative models have substantially expanded the landscape of MASLD assessment. This review summarizes current progress in non-invasive evaluation of MASLD from a clinically oriented perspective, covering traditional blood-based and clinical tools, omics approaches, quantitative imaging, and multimodal integration. Particular attention is given to how these tools may serve different clinical purposes, including targeted screening or case-finding, specialist referral, fibrosis stratification, prognostic assessment, longitudinal monitoring, and precision, risk-stratified care. Major translation barriers remain, including the predominance of technology-driven instead of clinically driven study designs, the imperfect nature of biopsy-based reference standards, insufficient head-to-head comparisons across modalities, limited external validation of high-dimensional models, and uncertainty regarding real-world implementation. We argue that the future of non-invasive assessment in MASLD lies not in identifying a universally superior single modality, but in developing a clinical-context-specific, stepwise, and biologically interpretable framework that aligns non-invasive tools with distinct clinical needs and decision points.

Authors

Institutions

Publication Details

Journal
Hepatoma Research
Published
2026-11-19
DOI
https://doi.org/10.20517/2394-5079.2026.69
Primary Topic
Liver Disease Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Non-invasive assessment in MASLD: from biomarker discovery to clinical pathway integration

Qianxue Shan, Yang Zhenghan, 余自强, Qiuyi Shen et al.
2 links
Hepatoma Research
Liver Disease Diagnosis and Treatment
article

Non-invasive assessment in MASLD: from biomarker discovery to clinical pathway integration

Qianxue Shan, Yang Zhenghan, 余自强, Qiuyi Shen, Dawei Yang, Hongjian Kang, Weitian Chen
article en

Abstract

Metabolic dysfunction-associated steatotic liver disease (MASLD) is one of the leading causes of chronic liver disease worldwide. Although liver biopsy remains the histological reference standard for assessing steatohepatitis, fibrosis stage, and therapeutic response, its invasiveness, sampling variability, and limited suitability for repeated monitoring have driven the development of non-invasive approaches. Clinical scores based on routine variables, omics-derived biomarkers, quantitative imaging techniques, and multimodal integrative models have substantially expanded the landscape of MASLD assessment. This review summarizes current progress in non-invasive evaluation of MASLD from a clinically oriented perspective, covering traditional blood-based and clinical tools, omics approaches, quantitative imaging, and multimodal integration. Particular attention is given to how these tools may serve different clinical purposes, including targeted screening or case-finding, specialist referral, fibrosis stratification, prognostic assessment, longitudinal monitoring, and precision, risk-stratified care. Major translation barriers remain, including the predominance of technology-driven instead of clinically driven study designs, the imperfect nature of biopsy-based reference standards, insufficient head-to-head comparisons across modalities, limited external validation of high-dimensional models, and uncertainty regarding real-world implementation. We argue that the future of non-invasive assessment in MASLD lies not in identifying a universally superior single modality, but in developing a clinical-context-specific, stepwise, and biologically interpretable framework that aligns non-invasive tools with distinct clinical needs and decision points.

Hepatoma Research
Chinese University of Hong Kong (HK)
Good health and well-being
Liver Disease Diagnosis and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon